Conference Track

Initial Therapy, Treatment Interruption, and Induction/Maintenance

Source: CCO Independent Conference Coverage of the 2004 International AIDS Conference*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Promising Observational Data on Lopinavir/Ritonavir Monotherapy in Treatment-Naive Patients
Survival Odds Improved With HAART Initiation Using WHO '3x5' Regimens
Long-term Risk of AIDS or Death Unchanged Despite Improvements in Response to HAART
CD4-Guided Treatment Interruption Compares Well to Continuous HAART
Lower CD4+ Cell Count Associated With Higher Prevalence of HIV X4 Phenotype
'Late Presenters' Commonly Present With Multiple AIDS Events, Yet Respond to Antiretroviral Treatment
Once-Daily Boosted Saquinavir Highly Effective at 24 Weeks
Encouraging Results for Lopinavir/Ritonavir Alone as Maintenance Therapy
Low Rate of Early Failure With Abacavir/Lamivudine NRTI Backbone Except for Triple-NRTI Regimen Containing Tenofovir
Sustained Virologic Response Achieved With Fosamprenavir in Antiretroviral-naive Patients
Virologic and Immunologic Response Sustained for 2 Years With Fosamprenavir Regimen in Treatment-naive Patients
Long-term Safety and Efficacy of Tenofovir DF in Antiretroviral-naive Patients
Current Risk of Viral Rebound in HAART-Treated Patients Related to Pre-HAART Antiretroviral Exposure
Equivalent Efficacy in Patients Initiating Treatment With PI-, NNRTI-, or NRTI-Based HAART
Injection-Drug Use Associated With Poorer Long-term Immunologic Response to HAART
Efavirenz-Containing Regimen Durable and Well Tolerated at 3 Years
Long-term Intermittent HAART Guided by CD4+ Cell Counts Over 2 Years
CD4+ Cell Count-Guided Treatment Interruption Safe for Patients With Durable Viral Suppression

Expert Analysis

Initial Therapy, Treatment Interruption, and Induction/Maintenance

Program Director: John P. Phair, MD

Faculty:

Joseph J. Eron, Jr., MD
Joel E. Gallant, MD, MPH
W. David Hardy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of options for first-line antiretroviral therapy
Review new findings regarding treatment interruption strategies
Describe the outcomes of recent studies evaluating induction/maintenance approaches to antiretroviral therapy

Earn CME credit by reading the expert analysis and commentary on initial therapy. Topics covered include:

Long-term Follow-up of GS 903: Tenofovir vs Stavudine
Other Long-term Efficacy Studies
First-line Boosted-PI Regimens
Treatment Interruption
Lamivudine Monotherapy vs Treatment Interruption
Induction/Maintenance Therapy With Abacavir/Lamivudine/Zidovudine
Induction/Maintenance Therapy With Lopinavir/Ritonavir Monotherapy
Insights From Cohort Studies

CREDIT INFORMATION

Release Date: August 19, 2004

Expiration Date: August 18, 2005

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 3.2 Nursing contact hours

Pharmacists: 2.75 contact hours (0.28 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.